MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX) CFO Gregory P. Hanson sold 11,232 shares of MabVax Therapeutics stock in a transaction on Friday, January 12th. The shares were sold at an average price of $0.96, for a total value of $10,782.72. Following the sale, the chief financial officer now directly owns 478,365 shares of the company’s stock, valued at approximately $459,230.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX) opened at $0.87 on Friday. The stock has a market capitalization of $19.90, a price-to-earnings ratio of -0.25 and a beta of 1.52. MabVax Therapeutics Holdings, Inc. has a 12-month low of $0.43 and a 12-month high of $3.57. The company has a current ratio of 0.54, a quick ratio of 0.54 and a debt-to-equity ratio of 0.80.

MabVax Therapeutics (NASDAQ:MBVX) last released its quarterly earnings data on Tuesday, November 7th. The company reported ($0.54) earnings per share (EPS) for the quarter. equities analysts forecast that MabVax Therapeutics Holdings, Inc. will post -3.01 EPS for the current year.

An institutional investor recently bought a new position in MabVax Therapeutics stock. Cambridge Investment Research Advisors Inc. purchased a new position in MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 2,495,203 shares of the company’s stock, valued at approximately $1,622,000. Cambridge Investment Research Advisors Inc. owned about 12.33% of MabVax Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 12.87% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “MabVax Therapeutics Holdings, Inc. (MBVX) CFO Sells $10,782.72 in Stock” was published by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright law. The original version of this news story can be viewed at

MabVax Therapeutics Company Profile

MabVax Therapeutics Holdings, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes proprietary human monoclonal antibody products and vaccines for the treatment of various cancers. The company has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers.

Insider Buying and Selling by Quarter for MabVax Therapeutics (NASDAQ:MBVX)

Receive News & Ratings for MabVax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MabVax Therapeutics and related companies with's FREE daily email newsletter.